As of Friday close, Marinus Pharmaceuticals Inc.’s (NASDAQ:MRNS) stock was up $0.5, moving up 7.63 percent to $7.05. The average number of shares traded per day over the past five days has been 835,960 shares. 1 time new highs have been achieved over the past 5 days, with a $0.23 gain in that time frame. In the last twenty days, the average volume was 706,440, while in the previous 50 days, it was 883,182.
Since last month, MRNS stock retreated -28.93%. Shares of the company fell to $6.06 on 08/16/23, the lowest level in the past month. A 52-week high of $11.15 was reached on 06/13/23 after having rallying from a 52-week low of $3.46. Since the beginning of this year, MRNS’s stock price has risen by 77.14% or $3.07, and marked a new high 32 times. However, the stock has declined by -36.77% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
MRNS stock investors should be aware that Marinus Pharmaceuticals Inc. (MRNS) stock had its last reported insider trading activity 11 days ago on Aug 08. Braunstein Scott, the CHAIRMAN AND CEO of the company, disposed of 30 shares for $8.94 on Aug 08. It resulted in a $268 divestment by the insider. Pfanstiel Steven sold 14 shares at an average price of $8.93 on Aug 08. The insider now owns 49,324 shares following the transaction. On Aug 08, CHIEF MEDICAL OFFICER Hulihan Joseph sold 13 shares at $8.93 apiece. The transaction was valued at $116.
Valuation Metrics
The stock’s beta is 1.41. Besides these, the trailing price-to-sales (P/S) ratio of 19.00, the price-to-book (PB) ratio of 6.47.
Financial Health
In the three months ended June 29, Marinus Pharmaceuticals Inc.’s quick ratio stood at 7.50, while its current ratio was 7.60, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 1.19, and the total debt-to-equity ratio was 1.26. On the profitability front, the trailing twelve-month gross margin is 97.50% percent. Based on annual data, MRNS earned $25.14 million in gross profit and brought in $25.48 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -63.90%. Return on equity (ROE) for the past 12 months was -35.30%.
In Marinus Pharmaceuticals Inc.’s quarter-end financial report for June 29, it reported total debt of $68.14 million against cash and short-term investments of $47.55 million. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. MRNS’s revenue rose 70.56% to $10.38 million during the quarter, while net income inched up to $6.08 million. While analysts expected Marinus Pharmaceuticals Inc. to report -$0.72 quarterly earnings, the actual figure was -$0.61 per share, beating the consensus estimate by 15.30%. During the quarter, the company generated -$31.55 million in EBITDA. The liabilities of Marinus Pharmaceuticals Inc. were 143.86 million at the end of its most recent quarter ended June 29, and its total debt was $107.16 million. The value of shareholders’ equity is $50.61 million.
Technical Picture
This quick technical analysis looks at Marinus Pharmaceuticals Inc.’s (MRNS) price momentum. With a historical volatility rate of 102.28%, the RSI 9-day stood at 34.00% on 18 August.
With respect to its five-day moving average, the current Marinus Pharmaceuticals Inc. price is up by +3.37% percent or $0.23. At present, MRNS shares trade -29.07% below its 20-day simple moving average and +12.62% percent above its 100-day simple moving average. However, the stock is currently trading approximately -13.39% below its SMA50 and +22.61% above its SMA200.
Stochastic coefficient K was 12.73% and Stochastic coefficient D was 7.94%, while ATR was 0.71. Given the Stochastic reading of 20.00% for the 14-day period, the RSI (14) reading has been calculated as 34.53%. As of today, the MACD Oscillator reading stands at -0.54, while the 14-day reading stands at -1.66.
Analyst Ratings
Marinus Pharmaceuticals Inc. downgraded its rating on Marinus Pharmaceuticals Inc. (NASDAQ: MRNS) to a Perform in a note to investors on August 11, 2023. The analysts firm previously had an Outperform rating on the stock.
